Market Overview

Benzinga's Top Upgrades, Downgrades For August 12, 2019

Share:

Upgrades

  • For Apple Hospitality REIT Inc (NYSE: APLE), Barclays upgraded the stock from Equal-Weight to Overweight. In the second quarter, Apple Hospitality REIT showed an EPS of $0.49, compared to $0.51 from the year-ago quarter. The total market value of Apple Hospitality REIT's outstanding shares is at $3.2 billion. At the moment, the stock has a 52-week-high of $17.99 and a 52-week-low of $13.81. Apple Hospitality REIT closed at $15.38 at the end of the last trading period.
  • Baird upgraded the stock for Axovant Gene Therapies Ltd (NASDAQ: AXGT) from Neutral to Outperform. The total market value of Axovant Gene Therapies's outstanding shares is at $146.4 million. At the moment, the stock has a 52-week-high of $20.80 and a 52-week-low of $3.81. Axovant Gene Therapies closed at $6.33 at the end of the last trading period.
  • Cantor Fitzgerald upgraded the stock for Humana Inc (NYSE: HUM) from Neutral to Overweight. For the second quarter, Humana had an EPS of $6.05, compared to year-ago quarter EPS of $3.96. The current market cap for Humana is at $45.9 billion. The stock has a 52-week-high of $355.88 and a 52-week-low of $225.65. At the end of the last trading period, Humana closed at $297.78.
  • Oppenheimer upgraded the stock for Instructure Inc (NYSE: INST) from Perform to Outperform. In the second quarter, Instructure showed an EPS of ($0.16), compared to ($0.24) from the year-ago quarter. Instructure's market cap stands at $1.4 billion. At the moment, the stock has a 52-week-high of $50.19 and a 52-week-low of $29.48. Instructure closed at $39.50 at the end of the last trading period.
  • Argus changed the rating for New Relic Inc (NYSE: NEWR) from Hold to Buy. New Relic earned $0.19 in the first quarter, compared to $0.15 in the year-ago quarter. New Relic shows a 52-week-high of $113.34 and a 52-week-low of $55.60. Moreover, at the end of the last trading period, the closing price was at $63.12.
  • Susquehanna changed the rating for National Oilwell Varco Inc (NYSE: NOV) from Neutral to Positive. In the second quarter, National Oilwell Varco showed an EPS of ($0.04), compared to $0.06 from the year-ago quarter. National Oilwell Varco shows a 52-week-high of $47.46 and a 52-week-low of $19.57. Moreover, at the end of the last trading period, the closing price was at $20.08.
  • For News Corp (NASDAQ: NWSA), Credit Suisse upgraded the stock from Neutral to Outperform. In the fourth quarter, News showed an EPS of $0.07, compared to $0.08 from the year-ago quarter. News's market cap stands at $9.4 billion. The stock has a 52-week-high of $15.44 and a 52-week-low of $10.65. At the end of the last trading period, News closed at $13.70.
  • For ONEOK Inc (NYSE: OKE), UBS upgraded the stock from Neutral to Buy. ONEOK earned $0.75 in the second quarter, compared to $0.68 in the year-ago quarter. The total market value of ONEOK's outstanding shares is at $28.7 billion. The stock has a 52-week-high of $72.38 and a 52-week-low of $50.26. At the end of the last trading period, ONEOK closed at $69.06.
  • UBS changed the rating for Wesco Aircraft Holdings Inc (NYSE: WAIR) from Sell to Neutral. In the third quarter, Wesco Aircraft Hldgs showed an EPS of $0.23, compared to $0.20 from the year-ago quarter. The current market cap for Wesco Aircraft Hldgs is at $975.4 million. The stock has a 52-week-high of $14.22 and a 52-week-low of $7.38. At the end of the last trading period, Wesco Aircraft Hldgs closed at $11.07.
  • Argus upgraded the stock for Zimmer Biomet Holdings Inc (NYSE: ZBH) from Hold to Buy. For the second quarter, Zimmer Biomet Holdings had an EPS of $1.93, compared to year-ago quarter EPS of $1.92. The total market value of Zimmer Biomet Holdings's outstanding shares is at $27.6 billion. At the moment, the stock has a 52-week-high of $139.71 and a 52-week-low of $96.99. Zimmer Biomet Holdings closed at $138.32 at the end of the last trading period.

 

Downgrades

  • William Blair changed the rating for bluebird bio Inc (NASDAQ: BLUE) from Outperform to Market Perform. bluebird bio earned ($3.55) in the second quarter, compared to ($2.91) in the year-ago quarter. The total market value of bluebird bio's outstanding shares is at $10.0 billion. At the moment, the stock has a 52-week-high of $176.55 and a 52-week-low of $87.49. bluebird bio closed at $125.23 at the end of the last trading period.
  • For Cambrex Corp (NYSE: CBM), Craig-Hallum downgraded the stock from Buy to Hold. In the second quarter, Cambrex showed an EPS of No EPS Value , compared to $0.74 from the year-ago quarter. The current market cap for Cambrex is at $88.0 million. At the moment, the stock has a 52-week-high of $69.42 and a 52-week-low of $33.80. Cambrex closed at $59.99 at the end of the last trading period.
  • KeyBanc downgraded the stock for Carrizo Oil & Gas Inc (NASDAQ: CRZO) from Overweight to Sector Weight. For the second quarter, Carrizo Oil & Gas had an EPS of $0.71, compared to year-ago quarter EPS of $0.79. The stock has a 52-week-high of $26.67 and a 52-week-low of $7.92. At the end of the last trading period, Carrizo Oil & Gas closed at $10.02.
  • Raymond James changed the rating for GTT Communications Inc (NYSE: GTT) from Outperform to Market Perform. GTT Communications earned ($0.59) in the second quarter, compared to ($2.83) in the year-ago quarter. The total market value of GTT Communications's outstanding shares is at $389.5 million. At the moment, the stock has a 52-week-high of $47.20 and a 52-week-low of $4.90. GTT Communications closed at $6.72 at the end of the last trading period.
  • DA Davidson downgraded the stock for Hanmi Financial Corp (NASDAQ: HAFC) from Buy to Neutral. Hanmi Financial earned $0.48 in the first quarter, compared to $0.46 in the year-ago quarter. The current market cap for Hanmi Financial is at $620.1 million. Hanmi Financial shows a 52-week-high of $26.93 and a 52-week-low of $17.56. Moreover, at the end of the last trading period, the closing price was at $19.86.
  • Roth Capital changed the rating for Hudson Technologies Inc (NASDAQ: HDSN) from Buy to Neutral. Hudson Technologies earned ($0.09) in the first quarter, compared to ($0.02) in the year-ago quarter. Hudson Technologies's market cap stands at $23.4 million. Hudson Technologies shows a 52-week-high of $2.25 and a 52-week-low of $0.50. Moreover, at the end of the last trading period, the closing price was at $0.55.
  • For Adesto Technologies Corp (NASDAQ: IOTS), Northland downgraded the stock from Outperform to Market Perform. For the second quarter, Adesto Technologies had an EPS of ($0.03), compared to year-ago quarter EPS of ($0.08). The total market value of Adesto Technologies's outstanding shares is at $82.8 million. Adesto Technologies shows a 52-week-high of $10.56 and a 52-week-low of $3.51. Moreover, at the end of the last trading period, the closing price was at $9.88.
  • For Lilis Energy Inc (AMEX: LLEX), SunTrust Robinson Humphrey downgraded the stock from Buy to Hold. Interestingly, in the third quarter, Lilis Energy's EPS was ($0.09). The current market cap for Lilis Energy is at $26.7 million. The stock has a 52-week-high of $5.69 and a 52-week-low of $0.28. At the end of the last trading period, Lilis Energy closed at $0.32.
  • For Livent Corp (NYSE: LTHM), Bank of America downgraded the stock from Neutral to Underperform. In the second quarter, Livent earned $0.12. The total market value of Livent's outstanding shares is at $1.7 billion. Livent shows a 52-week-high of $19.90 and a 52-week-low of $5.49. Moreover, at the end of the last trading period, the closing price was at $7.57.
  • H.C. Wainwright changed the rating for Melinta Therapeutics Inc (NASDAQ: MLNT) from Buy to Neutral. Melinta Therapeutics earned ($3.07) in the second quarter, compared to ($1.38) in the year-ago quarter. Melinta Therapeutics's market cap stands at $45.3 million. Melinta Therapeutics shows a 52-week-high of $25.75 and a 52-week-low of $1.62. Moreover, at the end of the last trading period, the closing price was at $2.85.
  • Baird downgraded the stock for Manitowoc Co Inc (NYSE: MTW) from Outperform to Neutral. Manitowoc Co earned $0.94 in the second quarter, compared to $0.40 in the year-ago quarter. The current market cap for Manitowoc Co is at $567.5 million. The stock has a 52-week-high of $26.88 and a 52-week-low of $13.22. At the end of the last trading period, Manitowoc Co closed at $16.98.
  • Goldman Sachs downgraded the stock for NetEase Inc (NASDAQ: NTES) from Buy to Neutral. For the second quarter, NetEase had an EPS of $4.09, compared to year-ago quarter EPS of $3.15. The total market value of NetEase's outstanding shares is at $18.4 billion. The stock has a 52-week-high of $289.69 and a 52-week-low of $184.60. At the end of the last trading period, NetEase closed at $242.90.
  • For OceanFirst Financial Corp (NASDAQ: OCFC), DA Davidson downgraded the stock from Buy to Neutral. OceanFirst Financial earned $0.51 in the second quarter, compared to $0.46 in the year-ago quarter. The current market cap for OceanFirst Financial is at $345.2 million. The stock has a 52-week-high of $29.71 and a 52-week-low of $21.30. At the end of the last trading period, OceanFirst Financial closed at $22.52.
  • Evercore ISI Group downgraded the stock for Occidental Petroleum Corp (NYSE: OXY) from Outperform to In-Line. For the second quarter, Occidental Petroleum had an EPS of $0.97, compared to year-ago quarter EPS of $1.10. The current market cap for Occidental Petroleum is at $45.6 billion. Occidental Petroleum shows a 52-week-high of $83.35 and a 52-week-low of $44.88. Moreover, at the end of the last trading period, the closing price was at $47.12.
  • Oppenheimer changed the rating for Stellus Capital Investment Corp (NYSE: SCM) from Outperform to Perform. In the second quarter, Stellus Capital Inv showed an EPS of $0.29, compared to $0.33 from the year-ago quarter. The total market value of Stellus Capital Inv's outstanding shares is at $265.0 million. At the moment, the stock has a 52-week-high of $15.30 and a 52-week-low of $11.65. Stellus Capital Inv closed at $13.89 at the end of the last trading period.
  • Wells Fargo changed the rating for Wright Medical Group NV (NASDAQ: WMGI) from Outperform to Market Perform. Wright Medical Group earned $0.02 in the second quarter, compared to ($0.03) in the year-ago quarter. Wright Medical Group's market cap stands at $866.0 million. The stock has a 52-week-high of $32.86 and a 52-week-low of $20.82. At the end of the last trading period, Wright Medical Group closed at $21.58.

 

Initiations

  • JP Morgan initiated coverage on AssetMark Financial Holdings Inc (NYSE: AMK) with a Neutral rating. The price target for AssetMark Financial Hldgs is set at $29.00. At the moment, the stock has a 52-week-high of $28.61 and a 52-week-low of $24.56. AssetMark Financial Hldgs closed at $26.30 at the end of the last trading period.
  • With a rating of Outperform, Raymond James initiated coverage on AssetMark Financial Holdings Inc (NYSE: AMK). The price target is set at $31.00 for AssetMark Financial Hldgs. The stock has a 52-week-high of $28.61 and a 52-week-low of $24.56. At the end of the last trading period, AssetMark Financial Hldgs closed at $26.30.
  • With a rating of Buy, Goldman Sachs initiated coverage on AssetMark Financial Holdings Inc (NYSE: AMK). The price target is set at $31.00 for AssetMark Financial Hldgs. The stock has a 52-week-high of $28.61 and a 52-week-low of $24.56. At the end of the last trading period, AssetMark Financial Hldgs closed at $26.30.
  • Mizuho initiated coverage on DTE Energy Co (NYSE: DTE) with a Neutral rating. The price target for DTE Energy is set at $131.00. In the second quarter, DTE Energy showed an EPS of $0.99, compared to $1.36 from the year-ago quarter. The current market cap for DTE Energy is at $18.0 billion. The stock has a 52-week-high of $132.09 and a 52-week-low of $106.41. At the end of the last trading period, DTE Energy closed at $129.33.
  • With a rating of Buy, Bank of America initiated coverage on Fulcrum Therapeutics Inc (NASDAQ: FULC). The price target is set at $19.00 for Fulcrum Therapeutics. Fulcrum Therapeutics's market cap stands at $290.5 million. The stock has a 52-week-high of $15.94 and a 52-week-low of $11.25. At the end of the last trading period, Fulcrum Therapeutics closed at $11.62.
  • With a rating of Overweight, Morgan Stanley initiated coverage on Fulcrum Therapeutics Inc (NASDAQ: FULC). The price target is set at $29.00 for Fulcrum Therapeutics. The total market value of Fulcrum Therapeutics's outstanding shares is at $290.5 million. At the moment, the stock has a 52-week-high of $15.94 and a 52-week-low of $11.25. Fulcrum Therapeutics closed at $11.62 at the end of the last trading period.
  • Morgan Stanley initiated coverage on Genmab A/S (NASDAQ: GMAB) with an Overweight rating. Genmab earned $0.18 in the first quarter, compared to $0.51 in the year-ago quarter. Genmab's market cap stands at $11.9 billion. Genmab has a 52-week-high of $19.05 and a 52-week-low of $12.10. Moreover, at the end of the last trading period, the closing price was at $18.94.
  • For Genmab A/S (NASDAQ: GMAB), Guggenheim initiated coverage, by setting the current rating at Buy. In the first quarter, Genmab showed an EPS of $0.18, compared to $0.51 from the year-ago quarter. The total market value of Genmab's outstanding shares is at $11.9 billion. At the moment, the stock has a 52-week-high of $19.05 and a 52-week-low of $12.10. Genmab closed at $18.94 at the end of the last trading period.
  • With a rating of Outperform, RBC Capital initiated coverage on Genmab A/S (NASDAQ: GMAB). The price target is set at $23.00 for Genmab. For the first quarter, Genmab had an EPS of $0.18, compared to year-ago quarter EPS of $0.51. The total market value of Genmab's outstanding shares is at $11.9 billion. Genmab shows a 52-week-high of $19.05 and a 52-week-low of $12.10. Moreover, at the end of the last trading period, the closing price was at $18.94.
  • Jefferies initiated coverage on Intra-Cellular Therapies Inc (NASDAQ: ITCI) with a Buy rating. The price target for Intra-Cellular Therapies is set at $16.00. Intra-Cellular Therapies earned ($0.68) in the second quarter, compared to ($0.68) in the year-ago quarter. The total market value of Intra-Cellular Therapies's outstanding shares is at $536.5 million. At the moment, the stock has a 52-week-high of $23.62 and a 52-week-low of $7.41. Intra-Cellular Therapies closed at $9.23 at the end of the last trading period.
  • For Mirum Pharmaceuticals Inc (NASDAQ: MIRM), Evercore ISI Group initiated coverage, by setting the current rating at Outperform. The current market cap for Mirum Pharmaceuticals is at $305.8 million. The stock has a 52-week-high of $15.46 and a 52-week-low of $12.05. At the end of the last trading period, Mirum Pharmaceuticals closed at $14.77.
  • With a rating of Outperform, Raymond James initiated coverage on Mirum Pharmaceuticals Inc (NASDAQ: MIRM). The price target is set at $28.00 for Mirum Pharmaceuticals. The current market cap for Mirum Pharmaceuticals is at $305.8 million. Mirum Pharmaceuticals shows a 52-week-high of $15.46 and a 52-week-low of $12.05. Moreover, at the end of the last trading period, the closing price was at $14.77.
  • With a rating of Buy, Citigroup initiated coverage on Mirum Pharmaceuticals Inc (NASDAQ: MIRM). The price target is set at $21.00 for Mirum Pharmaceuticals. Mirum Pharmaceuticals's market cap stands at $305.8 million. The stock has a 52-week-high of $15.46 and a 52-week-low of $12.05. At the end of the last trading period, Mirum Pharmaceuticals closed at $14.77.
  • Keefe Bruyette & Woods initiated coverage on Owl Rock Capital Corp (NYSE: ORCC) with a Market Perform rating. The price target for Owl Rock Capital is set at $16.00. Owl Rock Capital's market cap stands at $6.0 billion. At the moment, the stock has a 52-week-high of $16.45 and a 52-week-low of $15.02. Owl Rock Capital closed at $15.90 at the end of the last trading period.
  • With a rating of Outperform, RBC Capital initiated coverage on Owl Rock Capital Corp (NYSE: ORCC). The price target is set at $17.00 for Owl Rock Capital. The current market cap for Owl Rock Capital is at $6.0 billion. At the moment, the stock has a 52-week-high of $16.45 and a 52-week-low of $15.02. Owl Rock Capital closed at $15.90 at the end of the last trading period.
  • For Owl Rock Capital Corp (NYSE: ORCC), Wells Fargo initiated coverage, by setting the current rating at Market Perform. The current market cap for Owl Rock Capital is at $6.0 billion. The stock has a 52-week-high of $16.45 and a 52-week-low of $15.02. At the end of the last trading period, Owl Rock Capital closed at $15.90.
  • With a rating of Neutral, Bank of America initiated coverage on Owl Rock Capital Corp (NYSE: ORCC). The price target is set at $16.00 for Owl Rock Capital. The total market value of Owl Rock Capital's outstanding shares is at $6.0 billion. Owl Rock Capital has a 52-week-high of $16.45 and a 52-week-low of $15.02. Moreover, at the end of the last trading period, the closing price was at $15.90.
  • Raymond James initiated coverage on Owl Rock Capital Corp (NYSE: ORCC) with an Outperform rating. The price target for Owl Rock Capital is set at $17.00. The current market cap for Owl Rock Capital is at $6.0 billion. Owl Rock Capital has a 52-week-high of $16.45 and a 52-week-low of $15.02. Moreover, at the end of the last trading period, the closing price was at $15.90.
  • Ladenburg Thalmann initiated coverage on Owl Rock Capital Corp (NYSE: ORCC) with a Buy rating. The price target for Owl Rock Capital is set at $17.00. The current market cap for Owl Rock Capital is at $6.0 billion. At the moment, the stock has a 52-week-high of $16.45 and a 52-week-low of $15.02. Owl Rock Capital closed at $15.90 at the end of the last trading period.
  • SunTrust Robinson Humphrey initiated coverage on Owl Rock Capital Corp (NYSE: ORCC) with a Buy rating. The price target for Owl Rock Capital is set at $17.00. Owl Rock Capital's market cap stands at $6.0 billion. The stock has a 52-week-high of $16.45 and a 52-week-low of $15.02. At the end of the last trading period, Owl Rock Capital closed at $15.90.
  • With a rating of Overweight, Piper Jaffray initiated coverage on Phreesia Inc (NYSE: PHR). The price target is set at $33.00 for Phreesia. Phreesia shows a 52-week-high of $28.99 and a 52-week-low of $23.00. Moreover, at the end of the last trading period, the closing price was at $28.25.
  • Wells Fargo initiated coverage on Phreesia Inc (NYSE: PHR) with an Outperform rating. The stock has a 52-week-high of $28.99 and a 52-week-low of $23.00. At the end of the last trading period, Phreesia closed at $28.25.
  • With a rating of Buy, Craig-Hallum initiated coverage on Vicor Corp (NASDAQ: VICR). The price target is set at $43.00 for Vicor. Vicor earned $0.06 in the second quarter, compared to $0.19 in the year-ago quarter. The total market value of Vicor's outstanding shares is at $343.1 million. The stock has a 52-week-high of $64.50 and a 52-week-low of $26.50. At the end of the last trading period, Vicor closed at $28.97.

Posted-In: Initiations top upgradesUpgrades Downgrades Initiation Intraday Update Analyst Ratings

 

Related Articles (AMK + APLE)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
LOWRBC CapitalMaintains129.0
MARRBC CapitalMaintains148.0
CRLSunTrust Robinson HumphreyMaintains162.0
CFRSunTrust Robinson HumphreyMaintains105.0
ZYNEJefferiesAssumes11.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

As Colorado's Medical Market Finds A Plateau, Adult-Use Climbs 2x Higher

Monday's Market Minute: What A Difference A Week Makes…